Seong Mi Moon

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8888239/publications.pdf

Version: 2024-02-01

44 papers	1,308 citations	471509 17 h-index	361022 35 g-index
45 all docs	45 docs citations	45 times ranked	1279 citing authors

#	Article	IF	Citations
1	Outcomes of Mycobacterium avium complex lung disease based on clinical phenotype. European Respiratory Journal, 2017, 50, 1602503.	6.7	154
2	Epidemiology of Nontuberculous Mycobacterial Infection, South Korea, 2007â€“2016. Emerging Infectious Diseases, 2019, 25, 569-572.	4.3	113
3	Clinical Characteristics, Treatment Outcomes, and Resistance Mutations Associated with Macrolide-Resistant Mycobacterium avium Complex Lung Disease. Antimicrobial Agents and Chemotherapy, 2016, 60, 6758-6765.	3.2	90
4	Prognostic factors associated with long-term mortality in 1445 patients with nontuberculous mycobacterial pulmonary disease: a 15-year follow-up study. European Respiratory Journal, 2020, 55, 1900798.	6.7	89
5	Clofazimine-Containing Regimen for the Treatment of Mycobacterium abscessus Lung Disease. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	86
6	Complete remission in CD30-positive refractory extranodal NK/T-cell lymphoma with brentuximab vedotin. Blood Research, 2015, 50, 254.	1.3	60
7	Changing Epidemiology of Nontuberculous Mycobacterial Lung Diseases in a Tertiary Referral Hospital in Korea between 2001 and 2015. Journal of Korean Medical Science, 2018, 33, e65.	2.5	52
8	Development of Macrolide Resistance and Reinfection in Refractory Mycobacterium avium Complex Lung Disease. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 1322-1330.	5.6	46
9	In Vitro Activity of Bedaquiline and Delamanid against Nontuberculous Mycobacteria, Including Macrolide-Resistant Clinical Isolates. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	44
10	Peak Plasma Concentration of Azithromycin and Treatment Responses in Mycobacterium avium Complex Lung Disease. Antimicrobial Agents and Chemotherapy, 2016, 60, 6076-6083.	3.2	43
11	Amikacin Inhalation as Salvage Therapy for Refractory Nontuberculous Mycobacterial Lung Disease. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	41
12	Distribution and clinical significance of Mycobacterium avium complex species isolated from respiratory specimens. Diagnostic Microbiology and Infectious Disease, 2017, 88, 125-137.	1.8	39
13	Clinical Significance of Mycobacterium kansasii Isolates from Respiratory Specimens. PLoS ONE, 2015, 10, e0139621.	2.5	38
14	Long-term natural history of non-cavitary nodular bronchiectatic nontuberculous mycobacterial pulmonary disease. Respiratory Medicine, 2019, 151, 1-7.	2.9	38
15	Differences in drug susceptibility pattern between Mycobacterium avium and Mycobacterium intracellulare isolated in respiratory specimens. Journal of Infection and Chemotherapy, 2018, 24, 315-318.	1.7	35
16	Drug susceptibility patterns of Mycobacterium abscessus and Mycobacterium massiliense isolated from respiratory specimens. Diagnostic Microbiology and Infectious Disease, 2019, 93, 107-111.	1.8	29
17	Clinical characteristics and treatment outcomes of pulmonary disease caused by Mycobacterium chimaera. Diagnostic Microbiology and Infectious Disease, 2016, 86, 382-384.	1.8	26
18	Association between 16S rRNA gene mutations and susceptibility to amikacin in Mycobacterium avium Complex and Mycobacterium abscessus clinical isolates. Scientific Reports, 2021, 11, 6108.	3.3	24

#	Article	IF	Citations
19	miRNA Expression Profiles and Potential as Biomarkers in Nontuberculous Mycobacterial Pulmonary Disease. Scientific Reports, 2020, 10, 3178.	3.3	19
20	Mutations in gyrA and gyrB in Moxifloxacin-Resistant Mycobacterium avium Complex and Mycobacterium abscessus Complex Clinical Isolates. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	18
21	Diagnostic Performance of Radial Probe Endobronchial Ultrasound without a Guide-Sheath and the Feasibility of Molecular Analysis. Tuberculosis and Respiratory Diseases, 2019, 82, 319.	1.8	18
22	Comorbidity as a contributor to frequent severe acute exacerbation in COPD patients. International Journal of COPD, 2016, Volume 11, 1857-1865.	2.3	17
23	Non-intubated video-assisted thoracoscopic lung biopsy for interstitial lung disease: a single-center experience. Journal of Thoracic Disease, 2018, 10, 3262-3268.	1.4	17
24	Effect of Rifampin and Rifabutin on Serum Itraconazole Levels in Patients with Chronic Pulmonary Aspergillosis and Coexisting Nontuberculous Mycobacterial Infection. Antimicrobial Agents and Chemotherapy, 2015, 59, 663-665.	3.2	15
25	Prolonged Maintenance of VV ECMO for 104 Days with Native Lung Recovery in Acute Respiratory Failure. ASAIO Journal, 2016, 62, e15-e17.	1.6	15
26	Intermittent Antibiotic Therapy for Recurrent Nodular Bronchiectatic Mycobacterium avium Complex Lung Disease. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	15
27	Ipsilateral pleural recurrence after diagnostic transthoracic needle biopsy in pathological stage I lung cancer patients who underwent curative resection. Lung Cancer, 2017, 111, 69-74.	2.0	13
28	Treatment with a macrolide-containing regimen for Mycobacterium kansasii pulmonary disease. Respiratory Medicine, 2019, 148, 37-42.	2.9	12
29	Effect of Rifampin on Thyroid Function Test in Patients on Levothyroxine Medication. PLoS ONE, 2017, 12, e0169775.	2.5	12
30	Species Distribution and Macrolide Susceptibility of Mycobacterium fortuitum Complex Clinical Isolates. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	11
31	Intermittent Treatment with Azithromycin and Ethambutol for Noncavitary Mycobacterium avium Complex Pulmonary Disease. Antimicrobial Agents and Chemotherapy, 2019, 64, .	3.2	10
32	Genetic mutations in linezolid-resistant Mycobacterium avium complex and Mycobacterium abscessus clinical isolates. Diagnostic Microbiology and Infectious Disease, 2019, 94, 38-40.	1.8	10
33	Translation and validation of the Korean version of the clinical frailty scale in older patients. BMC Geriatrics, 2021, 21, 47.	2.7	10
34	Clinical Utility of Combined Circulating Tumor Cell and Circulating Tumor DNA Assays for Diagnosis of Primary Lung Cancer. Anticancer Research, 2020, 40, 3435-3444.	1.1	9
35	Comparative Study on the Effect of Cidofovir Treatment for Severe Adenovirus Pneumonia. Journal of Intensive Care Medicine, 2021, 36, 1436-1442.	2.8	8
36	Unresolved issues in treatment outcome definitions for nontuberculous mycobacterial pulmonary disease. European Respiratory Journal, 2019, 53, 1801636.	6.7	6

#	Article	IF	Citations
37	Nontuberculous Mycobacterial Lung Disease Caused byMycobacterium shinjukuense: The First Reported Case in Korea. Tuberculosis and Respiratory Diseases, 2015, 78, 416.	1.8	5
38	Effect of a 150Âmg dose of rifabutin on serum itraconazole levels in patients with coexisting chronic pulmonary aspergillosis and Mycobacterium avium complex lung disease. Journal of Infection and Chemotherapy, 2017, 23, 658-660.	1.7	5
39	Relationship between Resistance to Ethambutol and Rifampin and Clinical Outcomes in Mycobacterium avium Complex Pulmonary Disease. Antimicrobial Agents and Chemotherapy, 2022, 66, e0202721.	3.2	4
40	Purpura fulminans on the nose with septic abortion. Intensive Care Medicine, 2015, 41, 1122-1122.	8.2	3
41	Warfarin skin necrosis mimicking calciphylaxis in a patient with secondary hyperparathyroidism undergoing peritoneal dialysis. Kidney Research and Clinical Practice, 2016, 35, 55-58.	2.2	3
42	Lung cancer with superior vena cava syndrome diagnosed by intravascular biopsy using EBUS-TBNA. Respiratory Medicine Case Reports, 2016, 19, 177-180.	0.4	3
43	Clinical impact of forced vital capacity on exercise performance in patients with chronic obstructive pulmonary disease. Journal of Thoracic Disease, 2021, 13, 837-846.	1.4	3
44	Computed tomographic findings of macrolide-resistant Mycobacterium massiliense pulmonary disease and changes after antibiotic treatment. Medicine (United States), 2019, 98, e16826.	1.0	0